Rocket Lab Backlog Went to the Moon. The Stock Is Down Anyway. — Barrons.com

What happened

Rocket Lab reported third-quarter sales of $268 million and an EBITDA loss of $18 million, compared with analysts’ expectations of $257 million in sales and a $21 million loss. Its backlog, or contracted work awaiting completion, rose from $2.4 billion at the end of the second quarter to $3.6 billion. Shares fell after the report.

Confirmed

Global impact / market context

Higher sales and a larger backlog can support future revenue if Rocket Lab delivers the contracted work. But the company is not yet profitable, and its fourth-quarter outlook calls for an EBITDA loss of $14 million to $20 million, so costs and the pace of turning orders into sales remain important.

Analyst inference

The report shows why better results need not lift a stock: investors can weigh future growth against ongoing losses. Rocket Lab’s sales outlook for the fourth quarter is above analysts’ projection, while its expected loss is wider than their estimate.

Analyst inference

What to watch

1. Compare fourth-quarter sales with Rocket Lab’s $270 million to $290 million forecast and analysts’ $265 million projection to see whether growth is being delivered. Analyst inference
2. Check whether the $3.6 billion backlog becomes completed work and reported sales; delays or cancellations could weaken the revenue support implied by those orders. Analyst inference
3. Track the expected fourth-quarter EBITDA loss of $14 million to $20 million against the actual result; EBITDA is earnings before interest, taxes, depreciation, and amortization. Confirmed

Evidence

• Original source link unavailable